Simultaneous determination of a new anticancer drug galocitabine and its metabolites in blood by high-performance liquid chromatography

J Pharm Biomed Anal. 1993 Apr-May;11(4-5):379-84. doi: 10.1016/0731-7085(93)80032-v.

Abstract

A relatively simple and sensitive high-performance liquid chromatographic (HPLC) method is described for measuring galocitabine (Ro 09-1390) and its meatbolites, i.e. 5'-deoxy-fluorocytidine (5'-DFCR), 5'-deoxy-fluorouridine (5'-DFUR) and 5-fluorouracil (5-FU), in blood for the purpose of studying pharmacokinetics and toxicokinetics in small animals. The procedure for blood includes deproteinization with acetonitrile. Blood components were separated on a reversed-phase C18 column with a linear gradient of acetonitrile and water and detected at a wavelength of 270 nm. The between-day relative standard deviation (RSD) was less than 10% for all compounds at concentrations of 10-100 micrograms ml-1. The calibration curves obtained from the analysis of blood samples were linear and the correlation coefficients ranged from 0.997 to 0.999. The calculated determination limits were 6.9 micrograms ml-1 for galocitabine, 3.0 micrograms ml-1 for 5'-DFCR, 4.0 micrograms ml-1 for 5'-DFUR and 3.7 micrograms ml-1 for 5-FU.

MeSH terms

  • Animals
  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / toxicity
  • Chromatography, High Pressure Liquid
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / blood
  • Deoxycytidine / pharmacokinetics
  • Deoxycytidine / toxicity
  • Floxuridine / blood
  • Fluorouracil / blood
  • Indicators and Reagents
  • Rats
  • Spectrophotometry, Ultraviolet

Substances

  • Antineoplastic Agents
  • Indicators and Reagents
  • Floxuridine
  • Deoxycytidine
  • Ro 09-1390
  • Fluorouracil
  • doxifluridine